Felipe Fernández‐Vázquez
A5010450672- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Structural Anomalies and Repair
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Mechanical Circulatory Support Devices
- COVID-19 Clinical Research Studies
- Cardiac electrophysiology and arrhythmias
- Coronary Artery Anomalies
- Long-Term Effects of COVID-19
- Aortic aneurysm repair treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrest and Resuscitation
- COVID-19 and healthcare impacts
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Cardiac Ischemia and Reperfusion
- Cardiac Health and Mental Health
- Aortic Disease and Treatment Approaches
Hospital de León
2015-2024
Complejo Asistencial Universitario de Palencia
2014-2022
Centro de Investigación Biomédica en Red
2022
Universidad de Salamanca
2022
Centro de Investigación en Red en Enfermedades Cardiovasculares
2022
Universidad de León
2011-2020
Hospital Clínic de Barcelona
2020
Sociedad Española de Cardiología
2004-2018
Hospital Clínico San Carlos
2013
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
2013
The effect of β-blockers on infarct size when used in conjunction with primary percutaneous coronary intervention is unknown. We hypothesize that metoprolol reduces administered early (intravenously before reperfusion).Patients Killip class II or less anterior ST-segment-elevation myocardial infarction (STEMI) undergoing within 6 hours symptoms onset were randomized to receive intravenous (n=131) not (control, n=139) reperfusion. All patients without contraindications received oral 24 hours....
[Figure: see text].
Abstract Background and Aims Risk stratification for mitral valve transcatheter edge-to-edge repair (M-TEER) is paramount in the decision-making process to appropriately select patients with severe secondary regurgitation (SMR). This study sought develop validate an artificial intelligence-derived risk score (EuroSMR score) predict 1-year outcomes (survival or survival + clinical improvement) SMR undergoing M-TEER. Methods An was developed from EuroSMR cohort (4172 428 treated M-TEER...
In patients with acute myocardial infarction and ST-segment elevation (STEMI), primary angioplasty is frequently not available or performed beyond the recommended time limit. We designed a non-inferiority, randomized, controlled study to evaluate whether lytic-based early routine represents reasonable reperfusion option for victims of STEMI irrespective geographic logistical barriers.A total 212 were randomized full tenecteplase followed by stenting within 3-12 h randomization (early...
The aim of this study was to evaluate the outcome transcatheter mitral valve repair (TMVr) in patients with cardiogenic shock and significant regurgitation (MR). Patients severe MR have a poor prognosis setting conventional medical therapy. Because its favorable safety profile, TMVr is being increasingly used as an acute therapy population, though efficacy remains unknown. A multicenter, collaborative, patient-level analysis conducted. moderate (3+) or (4+) who were not surgical candidates...
Severe mitral regurgitation (MR) following acute myocardial infarction (MI) is associated with high mortality rates and has inconclusive recommendations in clinical guidelines. We aimed to report the international experience of patients secondary MR MI compare outcomes those treated conservatively, surgically, percutaneously.Retrospective registry consecutive at least moderate-to-severe 21 centres North America, Europe, Middle East. The included conservatively having surgical valve repair or...
Abstract Objectives To assess outcomes in patients with acute mitral regurgitation (MR) following myocardial infarction (AMI) who received percutaneous valve repair (PMVR) the MitraClip device and to compare of developed cardiogenic shock (CS) those did not (non‐CS). Background Acute MR after AMI may lead CS is associated high mortality. Methods This registry analyzed were treated at 18 centers within eight countries between January 2016 February 2020. Patients stratified into non‐CS groups....
Abstract Aims There is a lack of evidence regarding the benefits β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF). Methods and results The tREatment with Beta-blockers myOcardial withOut fracTion (REBOOT) trial pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical testing maintenance therapy in patients discharged MI or ST-segment elevation. Patients eligible...
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed assess the value of tricuspid annular plane systolic excursion (TAPSE) PA pressure (PASP) ratio non-invasive measure RV-to-PA...